Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ... (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve ... blocking the effects of the protein sclerostin and as a consequence building new bone formation.

Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and ...

"This positive CHMP opinion is a welcome milestone in the treatment of EGFR-mutated NSCLC, with the ability to make a meaningful difference in clinical practice and provide patients with more time to ...

The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that ...